Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Following consumer complaints, the manufacturers of weight loss drugs Wegovy and Zepbound have announced significant price drops in a move that could allow more Americans to access those medications.

Compounding pharmacies that have been selling hundreds of thousands of doses of copies of Lilly's Zepbound and Novo's Wegovy while the medicines were in shortage are running out of time to produce ...

"Demand for the medications Mounjaro, Zepbound, Ozempic, and Wegovy (GLP-1 drugs) has skyrocketed, but supply shortages and high costs have created opportunities for wrongdoers to cash in and ...

Semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic ... driven mainly by strong demand for Mounjaro and Zepbound. The company also reported that as more patients ...

After having removed Zepbound from its shortage list in December, the U.S. Food and Drug Administration on Friday removed Wegovy as well and told compounders to cease selling copies in the coming ...

The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have list prices ranging from $900 to $1,500 for a one-month supply. David Ricks, the CEO of Mounjaro and Zepbound ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic ... the brand names Mounjaro and Zepbound, was no longer in ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer ... the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro from competitor Eli Lilly had also ...

The drug's main rival, Novo Nordisk (NYSE:NVO)'s Wegovy, costs $650 for a month's supply to out-of-pocket patients and is not sold in vials. Still, Zepbound's latest offer of $499 per month for ...